Type 1 DiabetesHAGI-T1DNCT07564752
The Effect of Improved Glycemic Control on the Composition and Function of High-Density Lipoproteins (HDL) in Patients With Type 1 Diabetes
An observational study of Type 1 Diabetes, run by Centre Hospitalier Universitaire Dijon at 1 site in France.
Trial summary
The HAGI-T1D study aims to determine the effect of improved glycemic control on the composition and function of high-density lipoproteins (HDL) in patients with type 1 diabetes (T1D). It requires the establishment of a biological plasma/serum bank. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Type 1 Diabetes
- What is being tested?
- Blood test and Urine sample
- How many people
- 143 participants
- Where
- 1 siteFrance
- Study dates
- 25 Feb 2025to Nov 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients with type 1 diabetes whose condition is poorly controlled
Who may be able to join
- Control group non-diabetic and non-dyslipidemic :
- A person who has giver written consent
- Fasting blood glucose < 1,10 g/L
- Triglycerides < 1,50 g/L (< 1,70 mmol/L).
- HDL cholesterol > 1,03 mmol/L (men) or > 1,30 mmol/L (women).
- LDL cholesterol < 1,60 g/L.
Show all 10Show fewer
- Type 1 diabetes group :
- A person who has giver written consent
- Treated type 1 diabetes (regardless of the route of insulin administration).
- HbA1c > 8.0% (> 64 mmol/mol).
Who cannot join
- All participants :
- A person who is not enrolled in or eligible for a social security program
- A person subject to a legal protective measure (guardianship, tutorship)
- A person subject to a judicial protective measure
- Pregnant women, women in labor, or breastfeeding women
- Adults who are legally incompetent or unable to give informed consent
Show all 27Show fewer
- Minors
- Systemic inflammatory disease
- Medications that affect lipoprotein metabolism: immunosuppressive therapy, long-term corticosteroid therapy.
- Control group non-diabetic and non-dyslipidemic :
- Diabetes or use of an antidiabetic medication.
- Dyslipidemia or use of lipid-lowering medication.
- Cardiovascular disease (history of stroke, myocardial infarction, coronary artery disease).
- Kidney disease (glomerular filtration rate CKD-EPI < 75 mL/min/1.73 m²)
- Presence of metabolic syndrome defined by the presence of at least three of the following criteria (NCEP-ATP III criteria):
- waist circumference > 102 cm in men, > 88 cm in women;
- fasting triglycerides > 1.70 mmol/L ( > 1.50 g/L);
- HDL cholesterol > 1.03 mmol/L in men and 1.29 mmol/L in women;
- systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg;
- fasting blood glucose ≥ 6.10 mmol/L (≥ 1.10 g/L).
- Type 1 diabetes group:
- Diagnosis of type 1 diabetes within 12 months prior to enrollment.
- Glomerular filtration rate (CKD-EPI) < 60 mL/min/1.73 m².
- Albuminuria ≥ 30 mg/g creatinine.
- Initiation of lipid-lowering therapy within the month prior to the study.
- Type 1 diabetes group:
- Initiation of lipid-lowering therapy during the 3 months of the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Chu Dijon Bourgogne
Dijon
Benjamin BOUILLET, 03 80 29 34 53, benjamin.bouillet@chu-dijon.fr
About this study
Official title: Effect of Improved Glycemic Control on the Composition and Function of High-density Lipoproteins (HDL) in Patients With Type 1 Diabetes: a Prospective, Single-center Study. Comparison With Non-diabetic, Non-dyslipidemic Control Subjects. - HAGI-T1D Study
The HAGI-T1D study aims to determine the effect of improved glycemic control on the composition and function of high-density lipoproteins (HDL) in patients with type 1 diabetes (T1D). It requires the establishment of a biological plasma/serum bank.
T1D patients hospitalized in the Endocrinology-Diabetology-Metabolic Diseases Department at the Dijon Bourgogne University Hospital for poorly controlled diabetes (defined by glycated hemoglobin HbA1c >8.0%).
The study includes a T1D group of 80 patients with unsatisfactory glycemic control, who will undergo intensified therapy in accordance with standard clinical practice (modification of insulin therapy, therapeutic education, and lifestyle and dietary guidelines). The study also includes a control group of 63 non-diabetic, non-dyslipidemic subjects enrolled based on the results of laboratory tests from the screening visit to assess whether improved glycemic control in the T1D group restores anti-atherogenic functions and HDL composition to a level comparable to that of the control group.
- Conditions
- Type 1 Diabetes
- Being tested
- Blood test, Urine sample
- Medical subject headings
- Diabetes Mellitus, Type 1
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood testBiological
Performed on an empty stomach at the initial visit and then at 3 months
Urine sampleBiological
Performed only during the initial visit for patients with type 1 diabetes
| Study group | Role | What they receive |
|---|---|---|
| Patients with type 1 diabetes | Patients hospitalized in the Endocrinology, Diabetes, and Metabolic Diseases Department at the Dijon Bourgogne University Hospital due to poorly controlled diabetes. Receives: Biological: Blood test; Biological: Urine sample | |
| Control | Patients who are neither diabetic nor hypoglycemic Receives: Biological: Blood test |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difference in the percentage of HDL-induced stimulation of eNOS activation via phosphorylation at serine 1177 in human HUVEC endothelial cells
Measured: Between Month 0 and Month 3
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 May 2026
- Study start25 Feb 2025
- Primary completionNov 2027 (estimated)
- Study completionNov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 1 DiabetesStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire DijonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 143 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire Dijon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07564752
- Sponsor's protocol ID
- DENIMAL AOI 2023
- Acronym
- HAGI-T1D
- Status last verified
- Apr 2026
- First submitted
- 23 Apr 2026
- Last updated
- 4 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Improved Glycemic Control on the Composition and Function of High-density Lipoproteins (HDL) in Patients With Type 1 Diabetes: a Prospective, Single-center Study. Comparison With Non-diabetic, Non-dyslipidemic Control Subjects. - HAGI-T1D Study
- ClinicalTrials.gov ID
- NCT07564752
- Acronym / sponsor ID
- HAGI-T1D / DENIMAL AOI 2023
- Conditions
- Type 1 Diabetes
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 143 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire DijonUniversity, hospital or other
- Study start
- 25 Feb 2025 (actual)
- Primary completion
- Nov 2027 (estimated)
- Study completion
- Nov 2027 (estimated)
- First posted
- 4 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The HAGI-T1D study aims to determine the effect of improved glycemic control on the composition and function of high-density lipoproteins (HDL) in patients with type 1 diabetes (T1D). It requires the establishment of a biological plasma/serum bank.
T1D patients hospitalized in the Endocrinology-Diabetology-Metabolic Diseases Department at the Dijon Bourgogne University Hospital for poorly controlled diabetes (defined by glycated hemoglobin HbA1c >8.0%).
The study includes a T1D group of 80 patients with unsatisfactory glycemic control, who will undergo intensified therapy in accordance with standard clinical practice (modification of insulin therapy, therapeutic education, and lifestyle and dietary guidelines). The study also includes a control group of 63 non-diabetic, non-dyslipidemic subjects enrolled based on the results of laboratory tests from the screening visit to assess whether improved glycemic control in the T1D group restores anti-atherogenic functions and HDL composition to a level comparable to that of the control group.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients with type 1 diabetes | – | Biological: Blood test, Biological: Urine samplePatients hospitalized in the Endocrinology, Diabetes, and Metabolic Diseases Department at the Dijon Bourgogne University Hospital due to poorly controlled diabetes. |
| Control | – | Biological: Blood testPatients who are neither diabetic nor hypoglycemic |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with type 1 diabetes whose condition is poorly controlled
Key inclusion criteria (10 listed)
- A person who has giver written consent
- Fasting blood glucose < 1,10 g/L
- Triglycerides < 1,50 g/L (< 1,70 mmol/L).
- HDL cholesterol > 1,03 mmol/L (men) or > 1,30 mmol/L (women).
- LDL cholesterol < 1,60 g/L.
Key exclusion criteria (27 listed)
- A person who is not enrolled in or eligible for a social security program
- A person subject to a legal protective measure (guardianship, tutorship)
- A person subject to a judicial protective measure
- Pregnant women, women in labor, or breastfeeding women
- Adults who are legally incompetent or unable to give informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood testPerformed on an empty stomach at the initial visit and then at 3 months | Biological | Control, Patients with type 1 diabetes |
| Urine samplePerformed only during the initial visit for patients with type 1 diabetes | Biological | Patients with type 1 diabetes |
Primary outcome
Difference in the percentage of HDL-induced stimulation of eNOS activation via phosphorylation at serine 1177 in human HUVEC endothelial cells
Time frame: Between Month 0 and Month 3
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 May 2026.
Related trials for Type 1 Diabetes
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
RecruitingPhase 1
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Melanoma
Active, not recruitingPhase 2
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Metastatic Colorectal Cancer
Not yet recruiting
Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With Diabetes
Continuous Glucose Monitoring, Type 1 Diabetes
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Type 1 Diabetes, run by Centre Hospitalier Universitaire Dijon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 27 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Benjamin BOUILLET (03 80 29 34 53, benjamin.bouillet@chu-dijon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Difference in the percentage of HDL-induced stimulation of eNOS activation via phosphorylation at serine 1177 in human HUVEC endothelial cells (time frame: Between Month 0 and Month 3). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2026.